Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Poynard

Showing results (211-220 of 222) with videos related to

Pageof 23
Sort By:
Plos One|August 21, 2012
Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort studyHelmi M'Kada, Hugo Perazzo, Mona Munteanu, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Hepatology (Baltimore, Md.)|January 23, 2018
Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effortRachel J Church, Gerd A Kullak-Ublick, Jiri Aubrecht, et al.
Journal of Medical Virology|October 27, 2009
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapyFlorence Legrand-Abravanel, Philippe Colson, Hélène Leguillou-Guillemette, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Gastroenterology|March 23, 2002
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter studyRichard Moreau, Francois Durand, Thierry Poynard, et al.
Oncotarget|October 4, 2017
<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseAbderrahim Oussalah, Patrice Hodonou Avogbe, Erwan Guyot, et al.
Gastroenterology|July 31, 2012
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionEtienne Patin, Zoltán Kutalik, Julien Guergnon, et al.
Journal of Hepatology|May 15, 2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890Christophe Hézode, Hélène Fontaine, Céline Dorival, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 23

Showing results (211-220 of 222) with videos related to

Sort By:
Pageof 23
Plos One|August 21, 2012
Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort studyHelmi M'Kada, Hugo Perazzo, Mona Munteanu, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2021
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetesThierry Poynard, Valérie Paradis, Jimmy Mullaert, et al.
Hepatology (Baltimore, Md.)|January 23, 2018
Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effortRachel J Church, Gerd A Kullak-Ublick, Jiri Aubrecht, et al.
Journal of Medical Virology|October 27, 2009
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapyFlorence Legrand-Abravanel, Philippe Colson, Hélène Leguillou-Guillemette, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
Gastroenterology|March 23, 2002
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter studyRichard Moreau, Francois Durand, Thierry Poynard, et al.
Oncotarget|October 4, 2017
<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseAbderrahim Oussalah, Patrice Hodonou Avogbe, Erwan Guyot, et al.
Gastroenterology|July 31, 2012
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionEtienne Patin, Zoltán Kutalik, Julien Guergnon, et al.
Journal of Hepatology|May 15, 2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890Christophe Hézode, Hélène Fontaine, Céline Dorival, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Pageof 23